- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04548869
A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria
An Open Label, Phase 1 Single Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add on Therapy in Patients With Cold Contact Urticaria, Symptomatic Dermographism and Cholinergic Urticaria
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is an open label Phase 1 study evaluating the safety, pharmacokinetics, and pharmacodynamics of a single dose of CDX-0159 in patients with Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria who remain symptomatic despite treatment with antihistamines. Twenty patients with Cold Contact Urticaria, ten patients with Symptomatic Dermographism, and ten patients with Cholinergic Urticaria will be enrolled in four separate cohorts for a total of 40 patients.
Prospective patients will be screened with tests in clinic as well as daily at home diaries for 2 weeks prior to enrollment. CDX-0159 will be administered intravenously on Day 1. Post-treatment, patients will be followed for 12 weeks with an optional longer term follow up period.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10117
- Charité University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
Diagnosis of Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria which does not respond to antihistamines
- Diagnosis for ≥ 3 months; symptoms of both hive (wheal) and itch/burning/painful sensation despite concurrent use of anti-histamines
- During screening, in clinic, for Cold Contact Urticaria, patients must have a positive cold stimulation test, for Symptomatic Dermographism, patients must have a positive FricTest®, and for Cholinergic Urticaria, patients must have a positive pulse-controlled ergometry (PCE) provocation test
- On stable dose of antihistamines
- Other than a diagnosis of Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria, no other conditions which would introduce additional risk factors or would interfere with the study procedures, as determined by the investigator, based on a medical evaluation
- Female and male patients must use highly effective contraception from the time of the screening visit and for at least 150 days after receipt of study treatment
- Willing and able to comply with all study requirements and procedures including completion of a daily medication diary and questionnaires
Key Exclusion Criteria:
- A clearly defined diagnosis of hives or angioedema other than chronic urticaria.
- Receipt of prior biologic therapy (e.g.: omalizumab, dupilumab, ligelizumab) within past 3 months
- Treatment with immunosuppressives (e.g. systemic corticosteroids, cyclosporine, methotrexate, dapsone, cyclophosphamide, tacrolimus and mycophenolate mofetil, hydroxychloroquine or others) within 4 weeks or 5 half lives
- Active COVID-19 infection
- HIV, hepatitis B or hepatitis C infection
There are additional criteria that your study doctor will review with you to confirm you are eligible for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CDX-0159
20 patients with Cold Contact Urticaria, 10 patients with Symptomatic Dermographism, and 10 patients with Cholinergic Urticaria will be enrolled and treated with a single dose of CDX-0159
|
Administered intravenously
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety as assessed by the incidence and severity of adverse events
Time Frame: From Day 1 through week 12
|
Safety of a single dose of CDX-0159 as determined by adverse events
|
From Day 1 through week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
For patients with Cold Contact Urticaria, Change in Critical Temperature Thresholds (CTT)
Time Frame: From Day 1 to Day 85
|
The change from baseline in critical temperature thresholds over time as determined by provocation testing using the TempTest®
|
From Day 1 to Day 85
|
For patients with Symptomatic Dermographism, change in provocation thresholds
Time Frame: From Day 1 to Day 85
|
The change from baseline in provocation thresholds over time as determined by provocation testing using the FricTest®
|
From Day 1 to Day 85
|
For patients with Cholinergic Urticaria, changes in baseline Urticaria Activity Score Provocation (UASprovo)
Time Frame: From Day 1 to Day 85
|
Changes from baseline and percentage of responders as measured by UASprovo
|
From Day 1 to Day 85
|
Changes from baseline in Urticaria Control Test (UCT)
Time Frame: From Day 1 to Day 85
|
Changes from baseline and percentage of responders for the UCT and modified UCT
|
From Day 1 to Day 85
|
Blood Biomarkers
Time Frame: From Day 1 to Day 85
|
Pre-treatment and post-treatment blood samples will be collected and analyzed for changes in Stem Cell Factor
|
From Day 1 to Day 85
|
Blood Biomarkers
Time Frame: From Day 1 to Day 85
|
Pre-treatment and post-treatment blood samples will be collected and analyzed for changes in tryptase
|
From Day 1 to Day 85
|
Pharmacokinetic Evaluation
Time Frame: From Day 1 to Day 85
|
CDX-0159 concentrations will be measured.
|
From Day 1 to Day 85
|
Immunogenicity Evaluation
Time Frame: From Day 1 to Day 85
|
Patients will be monitored for the development of anti-drug antibodies.
|
From Day 1 to Day 85
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDX0159-03
- 2020-002792-35 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cold Urticaria
-
Charite University, Berlin, GermanyCompletedAcquired Cold UrticariaGermany
-
Third Harmonic Bio, Inc.TerminatedChronic Cold UrticariaNetherlands, Germany
-
Regeneron PharmaceuticalsCompletedGenetic Diseases, Inborn | Familial Cold Autoinflammatory Syndrome (FCAS) | Familial Cold Urticaria | Muckle-Wells Syndrome (MWS)United States
-
National Institute of Allergy and Infectious Diseases...Active, not recruitingHypersensitivity, Immediate | Autoinflammatory Syndromes | Physical Urticaria | Familial Cold Autoinflammatory SyndromeUnited States
-
Novartis PharmaceuticalsTerminatedChronic Spontaneous Urticaria | Cold Urticaria | Cholinergic UrticariaGermany
-
Marcus MaurerJohannes Gutenberg University MainzCompleted
-
Yuhan CorporationRecruitingAllergic Disease | Chronic Spontaneous Urticaria | Cold Urticaria | Chronic Inducible UrticariaKorea, Republic of
-
SanofiRegeneron PharmaceuticalsCompletedCold UrticariaUnited States, Argentina, Canada, Germany, Japan
-
Charite University, Berlin, GermanyRegeneron PharmaceuticalsCompleted
-
Charite University, Berlin, GermanyHospital del MarCompletedCold Contact UrticariaGermany
Clinical Trials on CDX-0159
-
Celldex TherapeuticsCompletedChronic Spontaneous UrticariaUnited States, Germany
-
Celldex TherapeuticsCompletedPrurigo NodularisUnited States, Germany, Poland
-
Celldex TherapeuticsCompleted
-
Celldex TherapeuticsActive, not recruitingChronic Inducible UrticariaUnited States, Latvia, Spain, Poland, Georgia, South Africa, Germany, Lithuania, Estonia, Hungary, Bulgaria
-
Celldex TherapeuticsActive, not recruitingChronic Spontaneous UrticariaSpain, United States, Poland, Georgia, South Africa, Bulgaria, Hungary, Estonia, Germany
-
TargetCancer FoundationFoundation MedicineRecruitingCholangiocarcinoma | Cancer of Unknown Primary Site | Rare CancersUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI); The Foundation for Barnes-Jewish Hospital; Celldex...TerminatedPancreatic Cancer | Pancreas Cancer | Cancer of the PancreasUnited States
-
Seoul National University HospitalUnknownBreast CancerKorea, Republic of
-
Celldex TherapeuticsCompleted